ArticleBMC microbiology2025
Extended-spectrum β-lactamase and carbapenemase-producing bacteria urinary tract infections in adult HIV-positive outpatients at Embu County Referral Hospital, Kenya.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) poses a significant threat to public health, with the Global Action Plan advocating, among others, for strengthening AMR knowledge and evidence base through surveillance and research and optimizing the use of antimicrobial medicines in human and animal health. However, due to inadequate healthcare infrastructure in many resource-constrained countries, epidemiological data to inform infection prevention interventions and guide antimicrobial policy guidelines in people living with HIV is limited. Here, we assessed the prevalence, antimicrobial resistance, and associated factors of bacterial urinary tract infections among adult HIV-positive outpatients in our study setting.
methodsThis was a hospital-based cross-sectional study among adult HIV-positive outpatients at Embu County Referral Hospital, Kenya, from January to February 2023. We consecutively recruited 142 patients presenting with or without UTI symptoms and excluded those aged below 18. Demographic and clinical data were collected using a pretested questionnaire, and midstream-clean-catch urine samples were processed by standard microbiological methods.
resultsThe overall prevalence of UTI was 9.9% (95% confidence interval (CI): 4.96-14.76% (14/142), with 6.3% symptomatic [95% CI: 2.33-10.35% (9/142)], 3.5% asymptomatic [95% CI: 0.49-6.55% (5/142)], and 4.2% recurrent [95% CI: 0.92-7.53% (6/142)] UTIs. Klebsiella pneumoniae was predominant overall (57.1%, 8/14), and in asymptomatic (80%, 4/5) and recurrent (66.7%, 4/6) UTIs. All the isolates were multidrug-resistant, with 36% (5/14) as meropenem-resistant and 14.3% (2/14) of carbapenem-resistant K. pneumoniae were colistin-resistant. E. coli isolates were susceptible to meropenem, amikacin, ciprofloxacin, and levofloxacin. The lowest resistance in K. pneumoniae was in amikacin (12.5%) and colistin (25%). Notably, 79% (11/14) and 35.7% (4/14) of the isolates were extended-spectrum β-lactamase (ESBL) and carbapenemase producers, respectively. Those with recurrent UTI were at higher odds of having UTI [adjusted odds ratio: 7.37, 95% CI: 1.93-28.07 (p = 0.003)].
conclusionsOur findings highlight a high prevalence of bacterial urinary tract infections, including recurrent ones caused by ESBL-, carbapenemase-producing, and colistin-resistant bacteria among HIV-infected adults. A comprehensive One Health approach is urgently required to reduce the burden of AMR among HIV-infected people through promoting responsible antibiotic use via the existing regulatory frameworks and knowledge transfer, as well as AMR uninterrupted surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.